A blend usually described as BPC-157 and TB-500. People commonly discuss it for injury recovery.
5-minute readFull profile reviewed July 25, 2026
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Wolverine stack at a glance
Why people look into it, what studies found, and what is still unknown.
Why people look into it
Whether the two ingredients together improve healing or recovery.
What studies found
No controlled study of a verified BPC-157/TB-500 blend was located. Small reports involving unclear combinations cannot establish that Wolverine works.
What is still unclear
The exact ingredients, ratio, combined effects, and safety remain unclear. Individual ingredient studies do not establish a blend dose or schedule.
About the evidence and review date
Educational information only. Evidence reviewed through July 25, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Why people research it
Each label shows how much evidence supports that question.
Injury and tissue-repair researchIngredient studies only
Tendon and ligament healingIngredient studies only
Knee-pain researchIngredient studies only
Benefit from combining BPC-157 and TB-500Not demonstrated
What studies show
What the evidence supports
The research behind the answer
For the combination, one confounded FDA adverse-event report and a
four-person subgroup exposed to BPC-157 plus material described as
thymosin beta-4. Neither establishes benefit, safety, or verified TB-500
exposure in a controlled study.
See each finding and its sources (9)
No direct evidence located
“Wolverine” is an informal community label for BPC-157 plus TB-500, not a standardized active pharmaceutical ingredient.
Peptide Relay uses the name to organize discussion of mixtures described as BPC-157 and TB-500. The label does not define a regulator-recognized identity, fixed ratio, salt form, formulation, or quality standard.
A name or label cannot verify what a particular material contains. Composition, ratios, salt forms, and manufacturing quality may vary.
Relay identity definition: This statement defines how Relay organizes a nonstandard community label. It is not an empirical outcome claim or verification of any product's contents.
No direct evidence located
No controlled or registered study of a verified BPC-157 and TB-500 combination was located.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a controlled or registered trial administering the verified two-component combination.
A no-results search is time-limited and cannot prove that no unpublished use has occurred.
FDA summarized one adverse-event report naming concurrent BPC-157 and TB500 exposure.
A 40-year-old woman reportedly developed diffuse skin hyperpigmentation and gingival darkening while using both materials, with recurrence upon rechallenge.
The report does not establish causation, incidence, product identity, or which material was responsible. FDA emphasized missing information and confounding factors.
The small knee-pain report does not demonstrate a Wolverine-stack benefit.
Only four people received BPC-157 plus material described as thymosin beta-4, there was no randomized comparison, and the report did not verify that the second material was TB-500.
An uncontrolled four-person subgroup cannot isolate a combination effect, measure tissue healing, or establish that TB-500 was administered.
Peer reviewedMethods, intervention groups, and outcomes
Regulatory sourceTB-500 identity as a seven-amino-acid fragment rather than full-length thymosin beta-4
Mechanistic rationale
Separate BPC-157 and TB-500 mechanisms do not establish complementary action or synergy.
BPC-157 has no identified molecular target, while TB-500 is discussed through fragment and actin-region hypotheses. Different proposed pathways do not show that the materials improve one another's effects.
Mechanistic plausibility is not evidence of clinical benefit, useful synergy, or reduced risk.
No evidence establishes mixture compatibility, stability, absence of interaction, or a synergy score for Wolverine.
No located study tested whether BPC-157 and TB-500 remain chemically and physically stable together, avoid aggregation, retain identity and potency, or produce a favorable biological interaction.
No duplicate named receptor and no known interaction are not evidence of compatibility or safety.
Regulatory sourcePeptide-related impurity, aggregation, immunogenicity, and limited-human-data concerns
Regulatory sourceTB-500 characterization, aggregation, and immunogenicity uncertainties
No direct evidence located
No approved dose, ratio, route, reconstitution method, or storage condition exists for Wolverine.
No approved fixed-combination product or clinical trial provides a universal preparation, administration, or handling process for BPC-157 plus TB-500.
A study protocol, nomination, or storage observation for one material cannot be transferred to a two-component mixture.
Regulatory sourceWithdrawn nomination and form-specific bulk-material observations
No direct evidence located
Wolverine is not FDA approved, and advisory votes on its ingredients do not approve the combination.
PCAC recommended possible 503A-list inclusion of BPC-157 and TB-500-related substances, but those votes were nonbinding and did not evaluate or approve a fixed-combination product.
Compounding eligibility, if finalized, would not establish FDA approval, effectiveness, safety, interchangeability, or combination compatibility.
FDA summarized one adverse-event report naming concurrent BPC-157 and TB500 exposure.
Other human evidence
The report does not establish causation, incidence, product identity, or which material was responsible. FDA emphasized missing information and confounding factors.
Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.
Side-effect frequency, study withdrawals, and gaps
How often side effects occurred
The available information does not reliably show how often particular side effects occur.
Evidence boundary
Under-detected or under-reported events must not be described as rare.
Why people stopped in studies
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundary
This is an evidence gap, not proof that discontinuations did not occur.
Warning information
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundary
No FDA-approved BPC-157/TB-500 fixed-combination product was located.
PCAC recommendations concerning each ingredient are nonbinding and do
not approve the combination. Both components are prohibited in sport.
Verified product identity, ratio, compatibility, stability,
pharmacokinetics, interactions, immunogenicity, dose-response,
adverse-event incidence, safety, and clinical effects of the actual
two-component mixture.
Emergency instructions
This profile does not contain verified, product-specific emergency instructions.
Evidence boundary
Relay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Dosing & preparation
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Route: Route unverified · No exact human administration route established in this review
Evidence gap · Route unverified
No verified regimen for this exact identity
Wolverine is a BPC-157/thymosin-related blend label with variable identity and ratio. Separate component records do not establish a blend protocol.
What would fill this gap: Exact component sequences, a defined ratio, and direct human combination evidence.
Dosing review checked Oct 20, 2026. Additional sources are available below.
Formulation & handling · Route unverified
No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose, maintenance, and trial targets explained
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Other source records, populations, and limits · all routes
No direct study for this identity
BPC-157 and TB-500 combination evidence
Amount in this source
A complete human regimen was not verified in this source record. See the dosing status above.
Frequency
Not established in controlled research
Route
No verified route for a reproducible two-component product
Duration
Not established in the reviewed record
Population, study design, and limitations
No controlled study was located that administered chemically verified BPC-157 and TB-500 together as a standardized combination.
Population: No directly studied human population was verified for this identity.
Design: No direct controlled or registered combination study located
A voluntary adverse-event report cannot establish incidence or causation, and a four-person uncontrolled subgroup did not verify the second material as TB-500.
The section remains incomplete because combination identity, compatibility, exposure, safety, and outcome evidence are absent.
No direct primary administration source was verified for this exact identity.
Mechanisms
How it works
The Wolverine label combines two distinct investigational peptides with
uneven evidence records. BPC-157 has predominantly preclinical evidence,
several small uncontrolled human reports, an incompletely reported
historical controlled study, and a recruiting Phase 2 trial without
results. TB-500 is a seven-amino-acid thymosin beta-4 fragment with
laboratory and animal evidence but no located controlled human study.
No pharmacokinetic, compatibility, stability, interaction, safety, or
efficacy trial of verified BPC-157 plus TB-500 was located. FDA's
BPC-157 review summarized one voluntary adverse-event report naming both
materials; that signal cannot establish causation or incidence.
Why this matters
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Signals and targets
No validated direct Wolverine targetNo validated molecular target for BPC-157No validated receptor target for TB-500
Proposed biological steps
BPC-157: proposed vascular, fibroblast, nitric-oxide, and inflammatory signaling
TB-500: proposed actin-region biology based on a seven-amino-acid fragment
No demonstrated combination mechanism or synergy
Research reference
How mature is the evidence?
A reference for the studies, populations, and routes behind this profile.
Research depthFragmentary combination reports
The human combination record is limited to one confounded adverse-event report and a four-person subgroup using unverified thymosin-beta-4 material.
Why this matters
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Evidence confidenceVery low for benefit or safety
No controlled trial verifies TB-500 exposure, isolates a combination effect, measures pharmacokinetics, or establishes adverse-event incidence.
Why this matters
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
Strongest evidenceOne FDA-summarized adverse-event report plus a four-person uncontrolled, identity-uncertain subgroupWhy this matters
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human evidenceDirect exposure reports exist, but no controlled evidence establishes benefit, safety, or verified TB-500 combination effectsWhy this matters
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Which product or study does this describe?
BPC-157 and TB-500 combination evidence: amounts and schedules describe this route record only.
Route studiedNo verified route for a reproducible two-component product
Schedules studiedNot established in controlled research
Amounts studiedWithheld: this record provides research context without a transferable amountWhy this matters
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-lifeNot established for this exact editorial recordWhy this matters
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Route evidenceNo controlled study was located that administered chemically verified BPC-157 and TB-500 together as a standardized combination.Why this matters
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A voluntary adverse-event report cannot establish incidence or causation, and a four-person uncontrolled subgroup did not verify the second material as TB-500. The section remains incomplete because combination identity, compatibility, exposure, safety, and outcome evidence are absent. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study-by-study record
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
Why this matters
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Other human evidencePeer reviewed
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
The two participants had no reported adverse effects or meaningful short-term laboratory changes during the pilot.
Study administration and important limits
Study administration: Intravenous BPC-157 under the pilot protocol; no TB-500
Limitations: Two short BPC-157-only observations cannot establish a population safety profile and provide no information about TB-500 or the combination.
Laboratory studyPeer reviewed
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats
PhaseTB-500 component evidence — not a Wolverine study
PopulationNot disclosed
DurationIn-vitro incubations and rat urine collection through 72 hours
Design and population
TB-500 metabolism in human-derived in-vitro systems and rats, with fibroblast scratch-wound assays
Human serum and microsomal systems, cultured fibroblasts, and rats
Outcomes measured
Peptide and metabolite identification
Fibroblast scratch-wound closure
Cell viability
What was reported
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Study administration and important limits
Study administration: TB-500 free base and synthesized metabolites under laboratory protocols; no BPC-157
Limitations: Laboratory and animal findings do not establish human TB-500 benefit, BPC-157 interaction, mixture compatibility, or a Wolverine-combination effect.
Other human evidencePeer reviewed
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
PhaseFour-person BPC-157 plus thymosin-beta-4 subgroup — TB-500 identity unverified
Population16 participants
DurationVariable follow-up; some responses reported beyond 6 months
Design and population
Uncontrolled retrospective chart review with follow-up questions
Sixteen people treated for heterogeneous chronic knee-pain conditions; four received two materials
Outcomes measured
Subjective knee-pain relief
Self-reported duration of relief
What was reported
Fourteen of 16 people reported some relief overall. Three of the four people in the two-material subgroup reported relief, but the study did not compare that subgroup with a randomized control.
Study administration and important limits
Study administration: Twelve people received BPC-157 alone; the first four also received material described as thymosin beta-4. The report did not verify that material as the seven-amino-acid TB-500 fragment.
Limitations: The report was retrospective, uncontrolled, unblinded, and based on subjective outcomes. Only four people received two materials, and the second material was not chemically verified as TB-500. It cannot establish a Wolverine-combination effect.
PhaseBPC-157 component trial — not a Wolverine study
Population120 participants
Duration14-day intervention with assessment through day 56 and recurrence follow-up
Design and population
Randomized, double-blind, placebo-controlled BPC-157 trial with standardized rehabilitation
Adults aged 18–45 with MRI-confirmed acute grade II hamstring strain
Outcomes measured
Time to unrestricted sport
MRI-assessed injury volume
Reinjury
Patient-reported function and pain
Safety
What was reported
No results are posted. The registration cannot establish benefit for BPC-157 or for the Wolverine combination.
Study administration and important limits
Study administration: Protocol-defined subcutaneous investigational BPC-157 or placebo; no TB-500
Limitations: This recruiting BPC-157-only trial has no posted results and does not test TB-500, the Wolverine combination, compatibility, or combined safety.
Other human evidenceRegulatory source
FDA evaluation of BPC-157-related bulk drug substances for the July 2026 Pharmacy Compounding Advisory Committee
PhaseFDA adverse-event report — not a controlled study
Population1 participants
DurationNot reported
Design and population
Voluntary FAERS report summarized in FDA's July 2026 BPC-157 evidence review
One 40-year-old woman
Outcomes measured
Diffuse hyperpigmentation
Gingival darkening
Recurrence upon rechallenge
What was reported
FDA summarized diffuse hyperpigmentation and gingival darkening that reportedly recurred when the combination was restarted.
Study administration and important limits
Study administration: Self-reported subcutaneous BPC-157 and TB500 twice daily; product identity, dose exposure, and concomitant substances were not independently verified
Limitations: A voluntary report cannot establish incidence or causation. FDA noted missing information and possible confounding, including concomitant medications. Product identity, purity, sterility, dose exposure, and attribution to either component or the combination were not established.
Community
Experience reports stay separate from published evidence
Loading Community Intelligence…
Built by the community
Help strengthen the Wolverine stack experience record
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.
Where to go next
Keep the question moving
Move from one profile into a direct comparison, a multi-compound evidence map, or a related record.